NPPA Excludes Eligible Patient Assistance Supplies from Cancer Drug Price Calculations

The National Pharmaceutical Pricing Authority has allowed qualifying anti-cancer drugs supplied free under manufacturer-run Patient Assistance Programmes to be excluded from trade margin calculations, subject to record-keeping and undertaking requirements. Government sales are also excluded from price-to-stockist calculations. The framework clarifies how manufacturers must determine regulated retail prices across different sales channels.